Replimune Group, Inc. — Director's Dealing 2022

Dec 6, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2022-12-01

Reporting Person: Xynos Konstantinos (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-12-01	Common Stock	A	17500	—	Acquired	70798	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-12-01	Employee Stock Option (right to buy)	$19.98	A	26250	Acquired	2032-12-01	Common Stock (26250)	Direct

Footnotes

F1: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on November 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until November 15, 2026, subject to the Reporting Person's continuous service to the Issuer.

F2: 25% of the shares underlying this stock option vest on December 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.